Natera (NASDAQ:NTRA) Stock: Insider Steven Leonard Chapman Sells 1,273 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 1,273 shares of Natera stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $413.31, for a total value of $526,143.63. Following the sale, the chief executive officer directly owned 96,926 shares of the company’s stock, valued at approximately $40,060,485.06. This trade represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The shares were sold at an average price of $320.99, for a total value of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The stock was sold at an average price of $266.39, for a total value of $819,415.64.
• On Tuesday, July 28th, Steven Chapman sold 3,580 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $909,570.60.
• On Monday, July 27th, Steven Chapman sold 2,190 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $570,473.10.

Natera Price Performance

Shares of NTRA stock opened at $400.65 on Wednesday. The stock has a market cap of $57.75 billion, a PE ratio of -294.59 and a beta of 1.50. The stock has a 50-day moving average of $338.71 and a 200-day moving average of $264.48. Natera, Inc. has a one year low of $167.33 and a one year high of $437.41.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same quarter last year, the firm earned ($0.74) EPS. Natera’s quarterly revenue was up 37.7% compared to the same quarter last year. As a group, research analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera and Alliance Foundation Trials announced AFT-70 NAVIGATE, a global randomized Phase III trial evaluating Genentech’s oral selective estrogen receptor degrader in breast cancer. Natera’s Signatera molecular residual disease test will help guide treatment decisions, potentially expanding adoption of its oncology testing platform. AFT-70 NAVIGATE trial announcement
• Positive Sentiment: The Phase III MRD-guided breast cancer study represents a meaningful commercial and clinical validation opportunity for Signatera, although revenue benefits will depend on trial outcomes and future adoption. Natera launches Signatera breast cancer trial
• Positive Sentiment: Guggenheim raised its price target for Natera to $475 from $360 and maintained a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Guggenheim raises Natera price target
• Neutral Sentiment: Natera reached a new 52-week high, reflecting strong momentum, but the move also leaves the stock vulnerable to consolidation. The shares trade well above their 50-day and 200-day moving averages. Natera reaches a 52-week high
• Negative Sentiment: CEO Steven Chapman sold 1,273 shares worth approximately $526,000 under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled and represents only about 1.3% of his holdings, it is a limited signal, but it may add short-term selling pressure. Natera CEO insider sale

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Robert W. Baird set a $348.00 price objective on shares of Natera in a research report on Friday, August 7th. BTIG Research lifted their target price on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, August 7th. TD Cowen boosted their target price on Natera from $325.00 to $340.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Morgan Stanley restated an “overweight” rating and issued a $355.00 price target on shares of Natera in a report on Monday, August 10th. Finally, UBS Group raised their price target on Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $347.02.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Trust Co. of Vermont bought a new position in Natera during the 2nd quarter worth about $26,000. Elevation Wealth Partners LLC bought a new stake in shares of Natera in the second quarter valued at about $30,000. Continuum Advisory LLC bought a new stake in shares of Natera in the second quarter valued at about $33,000. Reflection Asset Management acquired a new position in shares of Natera during the fourth quarter worth about $29,000. Finally, Rakuten Securities Inc. bought a new position in shares of Natera during the second quarter worth about $35,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.